FDA Grants Priority Review to Merck's Application for KEYTRUDA ® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinom February 25, 2025 by True Academy Comments are off Posted in:Stock Market & Investment NewsTagged with:Buy Sell ShareFTSEKLCIMalaysiaPelaburanSahamShare Trading See more Prev:Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients Back: All Posts Next:Nektar completes enrollment for alopecia study of rezpegaldesleukin